DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT06275958 by Leiden University Medical Center, with a registry enrolment figure of 587 participants, started 2024-07-01 and due to reach its primary completion in 2028-06. Interventions recorded: Doublet Chemotherapy, Standard Dose (100%); Doublet Chemotherapy, Dose-reduced (75%); Monotherapy, Standard Dose (100%); Monotherapy, Dose-reduced (75%). Conditions listed: Older Patients; Colorectal Cancer; Metastatic Cancer; Candidates for Palliative Chemotherapy. Primary outcome: Progression-Free Survival. Colorectal eligibility wording from the registry: "* Patients aged 70 years or older with colorectal cancer and distant metastases without localized treatment options". Sites: Netherlands. No results are recorded here; the registry entry is the source.